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ABSTRACT 
 
 
Despite tremendous progress within the field of oncology, highly metastatic forms 
of breast cancer remain particularly challenging to effectively treat. Systemically 
delivered chemotherapy with cytotoxic agents typically requires some convalescence 
time between treatments – allowing rapidly growing cancer types to develop resistance. 
Multidrug resistance, also known as pump-dependent, is particularly difficult to treat as it 
functions through overexpression of P-glycoprotein, an efflux pump which can produce 
resistance to a range of chemotherapeutics.  
We have previously developed the cationic micellar copolymer poly(lactide-co-
glycolide)-g-poly(ethylenimine) (PgP) and demonstrated its capacity as a vector for gene 
therapy. Here, we examine the capacity of PgP in mediating co-delivery of siRNA 
targeting P-glycoprotein (siMDR1) and the anthracycline class drug doxorubicin to 
mitigate multidrug resistance in drug resistant triple-negative human cancer cells in vitro. 
The results of this project have shown that PgP can be used to successfully bind siRNA 
into a complex that protects from interaction with charged particles through heparin 
competition assay, and remains stable in serum conditions. Results of MTT assay 
assessing metabolic activity have shown PgP/siMDR1 complexes to exhibit minimal 
cytotoxicity in vitro in comparison to untreated human MDA-MB-435 cancer cells. 
Assessment of silencing following treatment with PgP/siMDR1 complexes formed at 
various nitrogen:phosphate (N/P) ratios has shown significant knockdown of MDR1 
mRNA up 67%, in comparison to untreated groups of drug resistant MDA-MB-435 cells. 
PgP has also been shown to successfully load the hydrophobic chemotherapeutic 
 iii 
doxorubicin, improving the toxicity of the drug in vitro. These results show the efficacy 
of PgP as a vehicle for delivery of both doxorubicin and siMDR1 to drug resistant cancer 
cells, and may have potential for use in co-delivery of siMDR1 and chemotherapeutics in 
metastatic cancer treatment. Future studies will include in vivo toxicity and antitumor 
studies in athymic mouse breast cancer models.  
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CHAPTER ONE 
INTRODUCTION & BACKGROUND 
 
In 2005, cancer overtook cardiovascular disease as the leading cause of death in 
individuals under the age of 85 in the United States.1 In 2008, an estimated 7.6 million 
cancer deaths are thought to have occurred worldwide, with an incidence rate that has 
been steadily growing for decades.2,3 Breast cancer in particular accounts for 22.9% of all 
cancer occurrences and 14% of cancer related deaths in females, surpassed only by lung 
cancer as the cause of female cancer-related mortality,4 with an estimated 255,000 new 
cases diagnosed in 2017 in the United states alone and responsible for an estimated 
595,690 deaths in 2016.5-7 Advances in early detection methods such as mammography, 
Positron emission tomography (PET), and magnetic resonance imaging (MRI) have 
significantly reduced breast cancer mortality, (annual mammography alone has shown to 
reduce breast cancer mortality by 30% in women 50-69).8 However, the 5-year survival 
rate of patients with metastatic breast cancer remains disparately grim at less than 15%, 
with a median survival time of 18 months.7,9  Highly metastatic forms of cancer are those 
whose comprising cells, rather than remaining relatively contained within a primary 
tumor site, have an inordinate ability to migrate throughout the body and proliferate 
unchecked. This characteristic makes it very challenging to detect, localize, and 
ultimately treat the cancer cells effectively. This disparagingly large gap in treatment 
efficacies by stage demonstrates a clear need for more effective means of treating highly 
metastatic forms of breast cancer. Intratumoral (IT) administration of chemotherapeutics 
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is an obvious solution to the question of how to deliver drugs in cancer treatment, and in 
practice reduces systemic toxicity and increases drug action at local site. While common 
sense would dictate that this method would be ultimately insufficient for treating 
metastatic cancers, recent studies have actually shown that IT therapy can serve to 
generate an immune response against subsequent metastases, and when used prior to 
surgery on a primary tumor can serve to greatly reduce surgical morbidity or even kill the 
primary tumor by itself.10 That being said, some notable shortcomings of IT therapy 
include non-uniform distribution, rapid drug clearance, and ultimately low penetration 
rates as a result of the high pressure gradients. Overcoming these problems would require 
an effective means of both delivering and retaining chemotherapeutics within the tumor 
site. 
 
1.1 Metastasis and the Metastatic Niche 
Due to the competition inherent in the functionality of biological niches, it seems 
unlikely that the small populations of cells involved in initial metastatic seeding would be 
capable of producing the quantities of chemokines required for a gradient relevant to that 
of the primary tumor, indicating the existence of some additional process operating 
synergistically with those addressed above. In addition to the challenge and cost of 
investigating the mechanisms of this behavior, previously accepted theories of metastasis 
based on Steven Paget’s original ‘seed and soil’ hypothesis offered little to support or 
even justify the existence of such a phenomenon.11-13  
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As the understanding of metastasis has evolved, however, the identification and 
characterization of pre-metastatic and micrometastatic sites arising from Bernard and 
Weinberg’s dual proclivity model may serve to explain the tropism of cancer cells to 
these sites.14-17 Current understanding places strong association between cancer and with 
the widespread mobilization of inflammatory cells in the blood and hematopoietic cells, 
however bone marrow derived hematopoietic cells expressing vascular endothelial 
growth factor receptor 1 (VEGFR1) and the fibronectin receptor VLA4 (integrin α4β1) 
have been found to localize to pre-metastatic sites prior to seeding by cancer cells.18,19 
The recruitment of these cells are a result of both tumor secreted angiogenic cytokines 
such as VEGFA and placental growth factor (PIGF, which binds to VEGF1), as well as 
from S100 inflammatory chemokines and serum amyloid A3 (SAA3) expressed in 
response to VEGFA, transforming growth factor β (TGFβ), and tumor necrosis factor-α 
(TNF-α) release from the primary tumor.20-22 Sites which also exhibit notably higher 
stromal fibronectin expression which, in conjunction with the accumulated myeloid cells, 
would serve as effective docking sites for disseminating tumor cells and increase 
proliferation of cancer cells at these sites.19,23 
 
1.2 Current Treatment Methods  
Current treatment of breast cancer typically begins with an initial surgical 
intervention (lumpectomy, partial/full mastectomy, etc.), followed by radiation therapy in 
conjunction with either hormone therapy, chemotherapy, immunotherapy, or some 
combination of the three. The immediate challenge of surgical intervention is that not all 
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forms of breast cancer are easily localized; tumors that do not differ significantly in 
density or extracellular composition to the surrounding tissue are very difficult to remove 
completely, and highly metastatic forms are unlikely to be entirely localized to a single 
tumor.7  
Hormone therapy, one of the most common means of treating breast cancer, 
functions through antagonistic interaction with hormone receptors that are overexpressed 
in cancerous cells, and are understood to play a role in the rapid growth and proliferation 
of these cells. The three most well-known of these receptors are those for estrogen, 
progesterone, and HER2, and are the targets for most commercially available hormone 
therapy drugs24 
While effective in treating the roughly 85% of breast tumors that exhibit 
overexpression of at least one of these receptors, the mechanism by which this class of 
drug functions prevents them from having any therapeutic effect in the 15% of cases 
where these receptors are not expressed, commonly referred to as triple negative breast 
cancer.25 Highly proliferative and aggressive, triple negative breast cancers are typically 
managed by systemic chemotherapy. In addition to high cytotoxicity and a very narrow 
therapeutic window, this method of treatment alone is associated with high rates of 
recurrence, both local and systemic.26 
As possibly the most well-known method of treatment, chemotherapy through the 
systemic introduction of cytotoxic agents has long been proven to actively hinder growth 
and proliferation of cell populations in advanced breast cancer.27 Anthracyclines, a large 
class of chemotherapeutic drugs first developed in the early 1960s, remain among the 
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most effective anticancer drugs ever developed (e.g. fluorouracil, doxorubicin, 
cyclophosphamide).28 Despite half a century of rapid progress in the field of oncology, 
one of the first anthracycline drugs ever developed, doxorubicin (DOX, sold under the 
market name Adriamycin), remains on the World Health Organization’s list of essential 
medicines and recommended for systemic use in metastatic breast cancer; with demand 
such that as recently as 2014 the United States experienced a national shortage.29,30  
DOX functions by inducing apoptosis in cells via two distinct mechanisms: (1) 
Intercalation into DNA, which inhibits the activity of topoisomerase-II, an enzyme which 
is responsible for unzipping the DNA helix. In doing so, all of the cellular processes 
dependent on the functionality of topoisomerase-II are subsequently arrested, such as the 
replication, repair, and transcription of DNA. Intercalation can also result in histone 
eviction from transcriptionally active chromatin, further deregulating the DNA damage 
response in DOX exposed cells. (2) Cytosolic conditions equilibrate the oxidation of 
Doxorubicin to semiquinone in a reversible reaction that serves to produce reactive 
oxygen species capable of significantly damaging cellular DNA.31,32 
Occurring simultaneously within a cell, these mechanism cause DOX and other 
similarly functioning anthracyclines to exhibit potent apoptosis-inducing qualities. 
However, a number of serious limitations still exist that can severely hinder the 
effectiveness of clinical treatments dependent on the use of these agents. Depending on 
the drug, these limitations can include poor retention, non-specific distribution, toxicity, 
and the development of resistance in cancer cells.34-36 In fact, the cytotoxic characteristic 
of these agents that makes them so effective in mitigating the proliferation and growth of 
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cancerous cells is the very reason why cytotoxic chemotherapeutics alone will never 
prove to be the oncological panacea. This is due to the fact that cytotoxic agents currently 
available have no mechanism for selectivity; they affect cancerous and healthy cells 
indiscriminately. The severe side effects of chemotherapy are a result of the drugs 
functioning properly; the cell killing effects of the chemo drugs being active only on 
cancerous cells as well as the healthy cells in bone marrow, gastrointestinal epithelia, hair 
follicles, and cardiac musculature.37  
The damage on healthy cells caused by the action of these drugs results in the need 
for convalescence time between treatments, to allow for recovery of the population of 
these affected healthy cell types. Anthracycline-based regiments have objective response 
rates of 50-80%, with median response duration and survival times lasting from 10-18 
months and 18-26 months, respectively.9 The contrast between the purported efficacy of 
these drugs and the clinical data is likely indicative of the use of suboptimal doses and 
longer than ideal convalescence times between treatments to prevent acute/chronic 
toxicities and minimize damage to non-cancerous tissues.38 Due to the heterogeneous 
populations of cancer cells in tumors, especially fast growing tumors, this method of 
treatment fosters the rapid transition from a primarily drug sensitive population to an 
Figure 1. Schematic Representation of Resistance Acquisition in Cancer Populations by Cyclic Chemotherapy. After 
the first round of chemotherapy, cell population decreases significantly due to the death of sensitive cancer cells. 
Recovery time between chemotherapy sessions allows resistant cells to grow and take over the entire population 
(Orange: drug sensitive cells, Pink: drug resistant cells).33 
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entirely resistant population (Fig. 1). In many cases, the mechanism of the resistance 
acquired causes diminished efficacy in a range of drugs, often requiring the use of 
multiple chemotherapeutic agents with very different mechanisms of action over the 
course of treatment.39  
1.3 Multidrug Resistance 
There are two main pathways by which a population of cancer cells can become 
multidrug resistant (MDR), one being pump dependent and the other being non-pump 
dependent.40 Non-pump dependent MDR is characterized by an upregulation of proteins 
that inhibit the apoptotic pathway; Bcl-2 being the most commonly observed in this form 
of drug resistance.41 Since most common chemotherapeutic drugs such as doxorubicin or 
paclitaxel function within the cell by triggering apoptosis, non-pump dependent MDR 
can retard or even eliminate the efficacy of drugs while still facilitating an environment 
promoting the development of pump-dependent resistance.42  
Pump dependent MDR is characterized by an overexpression of P-glycoprotein 1, 
also known as multidrug resistance associated protein 1 (MDR1), a transmembrane drug 
efflux pump that functions to rapidly expel therapeutic agents from the cytosol into the 
extracellular domain before they can reach their site of action. This overexpression of 
MDR1 results in both a diminished efficacy of the drug and an increase in extracellular 
toxicity,42 and has been found to be a major contributor to chemotherapy failure in 
different MDR-overexpressing cancer types.43-45 This mechanism of drug resistance is 
particularly effective since, once developed, it can remove a wide range of drugs 
indiscriminant of their mechanism of action. While the use of drugs functioning via an 
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alternative mechanism of action has shown to be an effective method of mitigating the 
action of non-pump dependent resistance, overcoming pump dependent MDR has shown 
to require more complex methods of treatment, involving either drugs with a novel 
mechanism of inhibiting activity of efflux pumps, or some means of preventing 
expression of the genes coding for them.46 In order to most effectively overcome drug 
resistance in cancer populations to allow for successful long-term treatment with 
cytotoxic agents, simultaneous inhibition of both mechanisms must occur.47,48 Lastly, co-
treatment of cancer cells exhibiting MDR with siRNA-mediated gene silencing and 
chemotherapeutic drugs, administered separately, has shown to improve the overall safety 
and efficacy of treatment, however it is very likely that co-delivery of resistance-
inhibiting siRNA with chemotherapeutic drugs would be more efficient in treating cancer 
cell populations exhibiting MDR.36, 49 
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CHAPTER 2 
GENE THERAPY IN CANCER TREATMENT 
 
Gene therapy has shown great promise in treating gene-related disorders. Since the 
first successful clinical trial in 1990 treating Adenosine Deaminase Deficiency (ADA),50 
research in gene therapy has exploded from rare monogenic diseases to include potential 
applications in the treatment of complex conditions like cancer.51 Typical gene therapy 
approaches can be divided into two major categories based on action: function enhancing 
(such as through introduction of pDNA), and function inhibiting (such as gene silencing 
through RNAi). Gene silencing through RNA interference (RNAi), can effectively inhibit 
the expression of nearly any gene with high efficiency and specificity, and in doing so 
stop production of target proteins regardless of their function or structure.  
 
2.1 Function Interference 
The RNAi pathway is initiated by the presence of long double stranded RNA 
(dsRNA) (>200 base pairs) in the cytosol, which activates the enzymatic complex Dicer. 
The dsRNA is then processed and cleaved by Dicer into twenty-two double stranded 
fragments (20-25 base pairs) of small interfering RNA (siRNA) with a two nucleotide 
overhang on the 3’ ends of either strand. The dicer products then assemble with 
complexes containing endoribonuclease, which makes up the RNA-induced silencing 
complex (RISC), at which point the RNA strands separate, with the sense strand 
remaining in the cytosol to be degraded and the antisense strand remaining bound RISC, 
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activating the complex. Once activated, the RISC then identifies, binds, and cleaves any 
messenger RNA (mRNA) complimentary to the antisense strand bound to the RISC, 
preventing translation and selectively silencing gene expression.52,53 
Long dsRNA can be delivered to initiate the RNAi pathway, however the use of long 
dsRNA for gene therapy has been shown to present a number of delivery challenges. 
These challenges include transport through the plasma membrane, protection from serum 
nucleases, and preventing immunogenesis, all of which would make actual 
implementation in a therapeutic application impractical.54 Synthetic siRNA, however, 
bypasses several of the challenges of long dsRNA due to its reduced size, such as easier 
encapsulation in small delivery vehicles, and reduced immunogenicity.55,56  It is likely 
due to these reasons that siRNA is most common structure used in RNAi-based 
therapeutics.53 
In most studies attempting to use gene therapy in the treatment of cancer, target 
genes involved in the apoptotic or proliferative pathways are exploited to improve 
efficacy of adjuvant therapies.57 These have included function enhancing approaches 
delivering pDNA coding for proapoptotic genes such as TNF-α58 and p53,59 as well as 
function inhibiting approaches, delivering siRNA targeting antiapoptotic or resistance-
mediating genes such as Bcl-260 and MDR proteins.61 In particular, studies examining 
siRNA-mediated silencing of MDR proteins have shown some success in re-sensitizing 
cells to chemotherapeutics and improving treatment with anticancer drugs.62-65 That being 
said, few products have made it as far as clinical trials this far,66 often due to issues 
challenges of siRNA delivery. 
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2.2 Barriers to Treatment 
Gene therapy utilizing the RNAi pathway has enormous potential for clinical 
application; however, several major physiological barriers stand in the way of an 
effective siRNA-based therapeutic reaching the market anytime soon. In order to have 
any effect on gene expression, siRNA molecules must be delivered directly to the cytosol 
of target cells. Injection of naked DNA/RNA has been empirically shown to be fairly 
ineffective as a means of drug delivery within this field; the large size, negatively charge 
phosphate groups, and relative hydrophilicity all present immediate challenges 
individually capable of preventing nucleic acids from diffusing through cell membranes 
under normal conditions (e.g. passive diffusion), meaning that a delivery system that can 
selectively and efficiently deliver a gene to target cells is needed for successful gene 
therapy to occur.  
In addition to mediating endocytosis, an effective delivery system must be able to 
overcome (among others) several major barriers to successful gene silencing in vivo. 
These include: (i) a means of specificity, both in biodistribution as well as cellular 
uptake; (ii) protection against degradation by serum ribonucleases; (iii) preventing and 
delaying particle/siRNA clearance through the renal and reticuloendothelial systems; (iv) 
a mechanism to avoid or at the very least minimize interaction with serum proteins and 
non-target cells (it is in this regard, primarily, that bPEI falls short in satisfying all the 
requirements of an effective gene carrier); (v) minimization of complex immunogenicity 
and cytotoxicity in systemic circulation, and finally, (vi) to facilitate delivery into the 
cytosol of cells within the target population.53  
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Another major barrier to the delivery of siRNA in vivo is the need for particle 
protection in systemic circulation – be it from ribonucleases, serum proteins, non-target 
cell interactions, elution, or targeting by the immune system. Ribonucleases present in the 
blood will rapidly degrade free nucleic acids unless otherwise shielded from them. While 
this can be overcome through sheer volume of systemically introduced RNA or DNA, 
this process is far too inefficient for clinical application and can initiate an immune 
response, therefore a means of protecting the siRNA while in circulation is necessary.67 
Additionally, any non-native particles such as free nucleic acids also stand the risk of 
aggregation with serum proteins and non-target cells. Loading and protection from 
degradation of siRNA could be accomplished relatively easily via covalent binding or 
encapsulation within the particle, however the former of these methods would be 
unsuitable for siRNA mediated gene silencing due to its mechanism of action – free 
siRNA must be present within the cytosol of target cells to initiate assembly and 
activation of RISC. Therein lies one of the more complex aspects of delivering nucleic 
acid as opposed to traditional therapeutics – the siRNA must be bound to a vector such 
that it remains associated and protected by the particle in circulation, while readily 
dissociating from the complex once in the cytosol.68  
One potential method of binding siRNA to a particle that would allow this to occur is 
through electrostatic interaction, possible due to the strong negative charge associated 
with nucleic acids as a product of the contained phosphate groups. Complexation via 
electrostatic interaction with positively charged compounds would have the potential to 
facilitate both an appropriate binding strength and a means of spontaneous complexation.  
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While degradation by serum ribonucleases is a fairly simple challenge to overcome 
through the use of an appropriate drug delivery vehicle, the avoidance of protein binding 
has proven to require a more complex solution. With regards to opsonins of the adaptive 
immune system (e.g. antibodies) and cells of the innate immune system, overcoming this 
barrier has proved a challenge within the field of drug delivery for decades, with limited 
success.69 One of the most common methods of mediating protein binding (and 
subsequently opsonization) of nanoparticles is through the conjugation of a shielding 
group to the outer surface of the polymer. Some examples of shielding groups that have 
been heavily tested include polyacrylamide, poly(vinyl alcohol), and poly(N-vinyl-2-
pyrrolidone), however more recent studies have shown a clear preference to utilize 
polyethylene glycol (PEG), and PEG-containing copolymers.70-72 As evident by the 
examples listed, these shielding groups tend to be non-ionic surfactants with long 
hydrophilic polymer chains, which function to mediate protein binding through the 
formation of a hydration shell around the particle.70 In doing so, PEGylation can 
dramatically increase retention time in systemic circulation by effectively ‘hiding’ 
particles from serum proteins that would otherwise bind to them and target them for RES 
uptake.73,74 This has shown to be very effective, largely due to the fact that hydrophobic 
and electrostatic interactions are the primary forces involved in protein adsorption.75  
Despite the advantages associate with the use of cloaking polymers such as PEG, its 
incorporation onto nanoparticles for gene therapy presents several drawbacks as well. 
The effectiveness of PEG in surface charge shielding and preventing protein adsorption is 
also likely the cause of reduced complexation with nucleic acids shown in particles that 
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have been PEGylated, as well as diminished endocytosis and transfection efficiency.39,76 
More recent studies have also begun to indicate that PEG may in fact be more 
immunogenic than previously thought, which would challenge the candidacy of the 
polymer for use in long-term treatments.77  
As mentioned, many barriers exist to siRNA delivery that do not require attention 
in the delivery of pDNA. Despite all their similarities, pDNA and siRNA behave very 
differently due to some important differences. Stability is a major concern with RNA, 
which are vulnerable not only to base-catalyzed hydrolysis by their 2’-OH groups and the 
ribonuclease abundant in biological environments, but as siRNA are also susceptible to 
auto-hydrolysis at the 3’ overhangs necessary for optimal function.78 Another major 
difference that could have serious implications in behavior is size. The radically smaller 
size of siRNA, with a typical length of 18-25 bp, in comparison to pDNA, which could 
range anywhere between 1 and 200 kb,79 could result in very different behaviors in both 
drug delivery vehicles (DDVs) and a physiological environment– especially because their 
length is directly linked to overall charge. These factors must be kept in consideration 
when attempting to translate a vehicle previously used in pDNA delivery to that of 
siRNA 
2.3 Nanoparticles in Drug Delivery 
To first focus on specificity of delivery, while in systemic circulation an effective 
drug delivery vehicle must facilitate deposition within a specific area of activity- in the 
case of cancer this almost always means particle accumulation within a tumor or tumors. 
In this regard, the utilization of nanoparticles for drug delivery has a marked advantage 
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over other methods due to the utilization of the enhanced permeability and retention 
(EPR) effect as a means of passive targeting. The EPR effect is an intrinsic characteristic 
of colloidal particles in circulation, in which they exhibit systemic circulation times 
significantly higher than would otherwise be expected, and therefore an increased 
bioavailability and ability to permeate specific bodily tissues such as tumors.80 This effect 
is observed in particles with a diameter between approximately 10-100 nanometers, a size 
range at which the particles are too large for rapid elution through glomerular filtration by 
the renal system, while at the same time remaining too small for efficient identification 
and opsonization by the reticuloendothelial system (RET).81,82 The growth process and 
subsequent structure of tumors serves to create a number of important physiological 
characteristics that ultimately compound the impact of the EPR effect when used in 
oncological applications. Rapid angiogenesis, a hallmark of advanced and aggressive 
cancers, occurs during the both initial formation and tumor growth, as the high nutritional 
demands of the rapidly proliferating cells produce an environment that too hypoxic and 
nutrient-deficient to support themselves via diffusion at more than 1-2 mm removed from 
a blood supply.83-85 They respond to this deficiency by secreting a range of angiogenic 
growth factors, recruiting nearby vasculature to produce a huge network that due to rapid 
formation and chaotic cell growth is inefficient and disorganized.84 The poorly developed 
vascular junctions within this system are highly discontinuous.85 These openings allow 
for the passage of particles that are too large to pass through any smaller endothelial 
junctions such as the fenestrations of renal endothelium, much less the minute gap 
junctions of normal healthy vascular endothelium. This is significant in that the 
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circulating nanoparticles will be capable of not only highly permeating the tissue of 
tumors, but also doing so in a significantly higher degree relative to healthy tissues – 
thereby introducing a favorable degree of specificity with regards to particle 
biodistribution.86  Another unique characteristic of tumors is the incredibly poor 
hemodynamics, which arise partly from their poorly organized blood supply and partly 
from the complete lack of lymphatic drainage systems found in tumors. In the case of 
nanomedicine and EPR effect, this hemodynamic property serves to further encourage the 
retention of particulates within the previously specified size range.88 
2.4 Current Strategies 
The use of nanoparticles for application in clinical medicine is a practice that has 
been heavily researched since the early 1970’s, and has led to the development of a 
plethora of particle designs, varying wildly by size, composition, structure and function. 
Of that selection, there are two overarching classes of nanoparticle primarily considered 
as potential vectors for gene therapy: viral and non-viral vectors. Both of these carrier 
types have several subclasses with their own strengths and weaknesses that must be 
considered and weighed in relation to the application.  
Viral vectors are created through the use of a functional virus, in which the genes 
encoding a therapeutic protein have been inserted into a viral capsule so as to express the 
therapeutic RNA endogenously, while removing the genes responsible for viral activity 
that would be detrimental to the patient,  such as viral DNA synthesis, and the production 
of reverse transcriptase/integrase.89 Academic interest in viral vectors has waned over the 
last decade however, likely due to the severe potential drawbacks and the little-
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understood mechanisms behind them. Once a heavily researched topic, viral vectors have 
a number of advantages in comparison to non-viral alternatives including the potential for 
long-term expression of the target gene from only a single injection.90 Additionally, this 
biologically-derived approach builds upon thousands of years of evolutionary progress to 
the purpose of delivering genetic material to host cells, the result being a vector that is 
incredibly effective at transfecting even non-dividing cells such as those of the central 
nervous system.91  
While highly infective, many viral capsules are seriously limited by size, impacting 
their ability to deliver more complex RNA sequences.92 Adenoviral vectors, which have a 
fairly large capacity relative to other viral vectors and a linear double-stranded DNA 
genome, have proven to be applicable and actually quite effective in RNAi delivery.89 
Unfortunately, Adenoviral vectors also have the potential to elicit a strong immune 
response and liver toxicity.93 Adeno-associated viruses (AAV) have also been explored as 
vectors for gene therapy due to the fact that unlike the larger adenoviral vectors, AAV’s 
are non-pathogenic to humans, however they are also significantly smaller (~5.2 kB) and 
like adenoviral vectors are only transiently expressed.94,95 As long-lasting vectors capable 
of integration into a host’s genome, vectors produced from Retroviral and lentiviral (a 
subclass of retrovirus) sources have shown huge potential in the treatment of genetic 
disorders and even in suppression of diseases such as HIV-1, however like adenoviral 
vectors, serious concerns exist regarding the safety of these vectors.95,96 In summary, 
viral vectors have been shown to have huge potential in gene therapy applications, 
however a number of limitations present in all viral vectors regardless of subclass must 
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first be addressed, including limited loading capacity, immunogenicity, and risk of wild-
type virion regeneration.97-99  
Non-viral vectors for gene therapy are artificially produced carriers designed to 
assemble with siRNA to form complexes capable of delivering their complex genetic 
material to the cytosol of target cells. While much safer than their viral alternatives, non-
viral vectors come with their own drawbacks.68 Non-viral vectors have an effect that is 
inherently transient, and unlike viral vectors, they must address challenges such as 
mediating particle endocytosis and endosomal escape in the design of the particle. 
Subclasses of non-viral vectors include, among others, liposomes, lipoplexes, and 
cationic polymers.  
Liposomes are highly ordered nanoparticles that are composed of a lipid bilayer 
envelope which encapsulates an internal aqueous phase. In many ways liposomes are 
biomimetic structures, very closely resembling the phospholipid bilayer of the plasma 
membrane in cells. Liposomal nanoparticles have long been used for applications in drug 
delivery, having proven to be especially effective in delivering hydrophilic drugs via 
encapsulation within its aqueous core. Other notable advantages of using liposomes for 
drug delivery are its low cytotoxicity, ease of surface modification, and potential for self-
assembly.100 Unlike other non-viral vectors for gene therapy, liposomes can be loaded 
with siRNA just as easily as with any hydrophilic drug – in many cases by simply mixing 
solutions of the two components – loaded safely within the cell simply by 
encapsulation.100 Some drawbacks of liposome use for gene therapy include poor 
transfection efficiency and the lack of any means of mediating endocytosis or endosomal 
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escape, as well as a high risk of opsonization. However, these can be overcome via 
surface modification with other bioactive compounds capable of addressing these 
challenges.101 
Similar in composition to Liposomes, lipoplexes are formed when cationic lipids 
electrostatically complex with nucleic acids to produce a stable molecule capable of 
binding and protecting siRNA in systemic circulation.102 The use of cationic lipids 
provides several advantages over uncharged liposomes, the foremost being its ability to 
spontaneously associate with siRNA and the lipid bilayer of cells. This results in much 
higher cell internalization, both by endocytosis and by disruption of the cell’s plasma 
membrane (PM). The presence of a strong positive surface charge on these particles also 
has the potential to increase cytotoxicity, as well as phagocytosis/capture via the RES, 
which can drastically reduce residence time.103,104 
Cationic polymers, like cationic lipids, also spontaneously complex with siRNA due 
to ionic interactions between the cationic groups within the polymer and the phosphate 
groups of the siRNA to form a stable particle, with many similar properties to lipoplexes. 
Excessively high surface charges in these vector designs can result in high cytotoxicity 
and even spontaneous aggregation with abundant negatively charged blood proteins such 
as albumen and fibrinogen, which typically results in the rapid elimination from systemic 
circulation.81 While charge shielding could be accomplished via conjugation with stealth 
polymers, a major advantage of using cationic compounds to bind and deliver anionic 
nucleic acids is that the final surface charge of the complex is a function of the ratio 
between the protonated amine groups in the carrier’s structure and the negatively charged 
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phosphate groups of the bound nucleotides. This ratio is commonly described by the N/P 
ratio, and can be optimized based on the specific vector being examined. This system 
allows for the optimization of particle loading in terms of balancing toxicity and 
transfection efficiency. With exceptions to polymers conjugated to targeting moieties, 
most cationic polyplexes facilitate intracellular uptake by nonspecific endocytosis 
through interaction with heparin sulfate proteoglycans (HSPGs) present in the 
extracellular matrix.105 For this reason, polyplexes that maintain a slightly positive 
surface charge usually show improved stability and interaction with cell 
membranes,106,107 however this charge can also produce certain undesirable effects when 
used in vivo such as serum protein induced aggregation and excessive interaction with 
plasma membranes.108 
One well-known example of a cationic polymer used in polyplex formation is 
polyethylenimine (PEI). PEI is considered to be the ‘gold standard’ of non-viral gene 
delivery due to its high cellular uptake and endosomolytic activity, both essential aspects 
of transfection.109,110 While low molecular weight (MW) PEI variations have been 
investigated and found to have a somewhat lower cytotoxicity, high MW (25 kDa) PEI is 
much more commonly seen in studies investigating cationic polyplexes for gene therapy, 
likely due to its significantly higher transfection efficiency.39,111-113 This is because high 
MW PEI is incredibly effective in mediating both endocytosis and endosomal escape, 
two of the most challenging barriers to overcome with non-viral vectors. The branched 
version of PEI in particular (bPEI) has been shown to have highest efficiency and 
cytotoxicity – a result of the presence of primary amines throughout the branched 
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variation and their affinity for protonation at physiological pH compared to the secondary 
amines comprising linear PEI (lPEI) (for the remainder of this paper, it can be assumed 
that PEI is in reference to high MW bPEI unless otherwise specified).114,115 Other popular 
cationic vectors for siRNA delivery include polyamidoamine (PANAM) dendrimers, 
polylysine (PLL), and chitosan, however like PEI these polymers have not seen much 
success in vivo due to similar issues with efficiency and toxicity in biological 
conditions.106,116,117 
2.5 Endocytosis and the Proton Sponge Effect 
While PEI has been reported to enter the cell via a combination of mechanisms 
partially dependent on particle size, having been documented entering cells through 
clathrin and caveolin-mediated endocytosis as well as macropinocytosis, recent studies 
have shown that these mechanisms are not solely responsible for all PEI endocytosis.118-
120 One proposed hypothesis to account for this finding, as well as the synergistic effect 
of cationic charge on siRNA delivery is that ionic interactions between the cationic 
polymer (such as PEI) and the PM result in the transient disruption of the PM to create 
nanoscale holes capable of permitting particle transport into the cell.121 Interestingly 
enough, the same interaction between cationic polymers and the outermost bilayer has 
been proposed by several research groups as the cause of the cytotoxicity seen in cationic 
polymers.122,123 While particles entering the cell through this proposed mechanism would 
be safe from endosomal degradation, the high transfection efficiency of PEI compared to 
other cationic polymers indicates the action of another mechanism at work – endosomal 
escape.  
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Endosomal escape is a critical function of an effective gene carrier, as it can 
dramatically improve transfection.124 Failure for endosomal escape to occur would 
otherwise result in complex degradation from the acidic environment as well as the 
proteases and peroxidases that accumulate as the early endosome reaches maturation.125 
The most commonly accepted mechanism that has been proposed to explain PEI’s 
apparent ability to escape the early endosome is known as the “proton sponge” effect, 
hypothesized to occur with other cationic polymers such as PAMAM and chitosan, and 
utilize the buffering capacity of tertiary and secondary amine groups to inhibit endosomal 
acidification. The theory proposes that as the pH begins to drop in the early endosome, 
protonation of amine groups in the polymer that exhibit pKa values between neutral and 
lysosomic pH inhibits further acidification of the endosome. While reports from 
Benjaminsen et al. have indicated that this is not in fact the case, and that the endosome 
eventually reaches a normal pH not below 5.5,126,127 this is not to say that his results 
invalidate the theory – in fact Benjaminsen and Richard et al. both argue that these results 
simply indicate that while functioning as a ‘proton sponge,’ the V-ATPase pump 
responsible for stabilizing the pH of the endosome is capable of overcoming this 
effect.126,127 In any case, the buffering capacity of the PEI results in the influx of protons 
to the endosome by the V-ATPase pumps in the process of stabilizing endosomal pH. 
The presence of both free protons and the protonated primary and secondary amine 
groups within the PEI result in the formation of an electrochemical gradient responsible 
for the endosomal transport of large chloride ions into the endosome, in turn creating an 
osmotic gradient responsible for the influx of water into the endosome. The influx of 
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these protons, counter-ions, and water result in the swelling and ultimately rupturing of 
the endosome, releasing its contents into the cytosol.128,129 Once taken up by a target cell 
and exposed to the acidic conditions, the siRNA should be able to disassociate from the 
complex and diffuse throughout the cytosol.130 
2.6 Poly(ethylenimine) and Strategies for Improvement 
While touted as the gold standard of non-viral vectors in gene delivery, there still 
exists a significant gap between PEI’s impressive efficiency in non-serum conditions and 
its relative ineffectiveness in serum conditions.131,132 Most likely this is a result of particle 
stability being less than ideal, the polymer strands comprising the complex readily 
aggregating to the abundant anionic serum proteins or erythrocytes in the blood.133 This 
explanation for the performance of PEI seems reasonable when considering the ionic 
interactions of the nucleic acids and the cationic polymer are the only forces holding the 
complex together.68 PEI’s poor serum performance being a result of complex instability 
is further supported by the drop in transfection efficiency and aggregation observed in 
lyophilized samples as well as samples diffused out of hydrogel-based scaffolds.134-136 
One promising method of improving cationic polyplex stability that has been investigated 
is grafting with hydrophobic polymers. In addition to improving colloidal stability, the 
use of amphiphilic block copolymers for complexation with nucleic acids has been shown 
to increase transfection efficiency and decrease cytotoxicity.131,137,138 Specifically, vectors 
that assemble into a micelle formation through incorporation of hydrophobic polymers 
also have shown to reduce charge density and improve the particle’s capacity to facilitate 
endosomal escape.139 In the specific case of bPEI, one of the most effective modifications 
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of the polymer to date has been accomplished by conjugation with low MW hydrophobic 
groups.140 Micelle formation is primarily driven by two highly cooperative forces: 
hydrophobic interactions between the hydrophobic regions of the amphiphilic polymer, 
and electrostatic attraction between the negatively charged nucleic acids and the cationic 
regions of the polymer.141, 142 Micelles will form spontaneously at or above the critical 
micellar concentration (CMC), and have shown to contribute heavily to particle 
stability.143 
Having established the need for effective drug delivery systems for the application of 
both chemotherapeutics and nucleic acids, as well as the advantages of co-delivery over 
just concurrent treatment, the need for a multifunctional vector capable of specific and 
combinatorial delivery of these therapeutic agents is quite apparent.144 While this particle 
would necessarily be used in adjuvant treatments, the successful implementation of such 
a complex could represent a sorely needed advancement on current treatments. 
 
 25 
CHAPTER 3 
RESEARCH AIMS 
 
3.1 Objectives 
While many advances in oncology have improved patient outlook and overall 
mortality, the development of multidrug resistance remains a critical obstacle in the 
development of treatments in breast cancer. The goal of this research is to develop a dual-
functional nanotherapeutic for the mitigation of multidrug resistance in metastatic breast 
cancer. This study is designed around the hypothesis that combinatorial therapy with 
doxorubicin and siRNA silencing P-glycoprotein will serve to concurrently re-sensitize 
drug resistant cells to critical chemotherapeutics while delivering said drug to the newly 
sensitized cells. This study will focus on in vitro analysis of both doxorubicin and 
siMDR1 delivery to cells as mediated by PgP. 
 
3.2 Vehicle Design  
The cationic micellar copolymer Poly(lactide-co-glycolide)-graft-
poly(ethylenimine) (PgP) is a novel design (figure 2) synthesized by conjugating the 
cationic polymer PEI to the hydrophobic block copolymer PLGA, creating a structure 
that should retain the characteristics of PEI that made it such a promising vehicle for gene 
therapy – namely its ability to electrostatically bind and intracellularly delivery nucleic 
acid, as well as its buffering capacity within early endosomes. A major barrier of PEI to 
use in therapeutic applications is its relative inability to function in serum conditions due 
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to issues of stability and interaction the charged particles present in high protein 
conditions. By conjugating the polymer to PLGA, the produced particle should exhibit 
improved stability due to hydrophobic interactions and the spontaneously arising micellar 
structure of the particle at concentrations above the critical micellar concentration 
(CMC). The hydrophobic PLGA core should be capable of loading hydrophobic drugs 
while providing stability to the particle, with the PEI in the corona of the micelle being 
able to electrostatically bind nucleic acids such as pDNA or siRNA due to the presence of 
cationic amine groups. The complexed particle size has been characterized at a diameter 
of approximately 120 nm, within optimum range for exploitation of the EPR effect – 
being too large for rapid expulsion by glomerular filtration but too small for targeting by 
opsonization and elimination by the reticuloendothelial system – while passively 
targeting and accumulating in tumorous tissue as a result of the poor hemodynamics and 
endothelial disfunction arising from their rapid and disorganized growth. Once 
accumulated, it can be endocytized, facilitating endosomal escape into the cytosol via the 
Figure 2. PgP Micelle Design. The micellar structure of PgP, where black lines represent the PLGA blocks and 
red lines represent PEI chains within the PgP polymer. 
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proton sponge effect – an inherent characteristic arising from the buffering capacity of 
secondary amine groups within the PEI branches. Once in the cytosol, their nucleic acid 
load can begin to function, and the action of any loaded anthracycline-class 
chemotherapeutics will be drastically be improved by delivery to the site of action. 
 
3.3 Study Outline 
 In order to determine the ability of PgP to function as designed, the suitability of 
PgP as a delivery vehicle for both siRNA and hydrophobic chemotherapeutics must be 
examined. The stability of PgP/siRNA will be assessed, as well as its ability to function 
in vitro in simulated physiological conditions (i.e. in serum). Initially, this will be 
determined by testing the ability of PgP to transfect MDA-MB-435 ADR and wild type 
cells with pGFP, as well as the cytotoxicity of the polymer in both cell types. Should the 
initial results show PgP to be an effective vector for pDNA delivery with minimal 
toxicity in this cell line, stability can be determined by heparin competition assay to 
determine the stability of the PgP/siRNA micelles in competition with other charged 
particles, as well as the stability of siRNA-bound complexes relative to the pGFP-bound 
complexes, which have already been shown to be effective in transfection of other cell 
lines. This will be followed by in vitro analysis of both cytotoxicity and its ability to 
successfully silence the MDR1 gene, on both the mRNA and protein level, in MDA-MB-
435 ADR cells when complexed with siMDR1. Doxorubicin loading in PgP will also be 
assessed, through photospectrometry to determine loading efficiency, and then 
cytotoxicity by MTT assay of MDA-MB-435 ADR cells treated at varying concentrations 
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to determine the optimum loading concentration. Finally, the practical efficacy of co-
delivering doxorubicin with siMDR1 will be assessed by cytotoxicity studies of both co-
delivered siMR1 and doxorubicin in the form of DOX/PgP/siMDR1 complexes. Future 
studies can include in vivo antitumor, biodistribution, and toxicity studies in athymic 
nude mice using induced MDA-MB-435 ADR tumors and intratumoral treatment with 
the fully loaded and complexed particle. 
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CHAPTER 4 
MATERIALS & METHODS 
 
4.1 Materials 
Poly(lactide-co-glycolide) (PLGA, ~4 kDa 50:50) was purchased from Durect 
Corporation (Pelham, AL), with a carboxylic end group. Branched poly(ethylenimine) 
(PEI, 25 kDa), as well as Thiazolyl Blue Tetrazolium Bromide, and RPMI 1640 was 
purchased from Sigma-Aldrich (St. Louis, MO). The wild type (WT) and Doxorubicin-
resistant (ADR) MDA-MB-435 cells were provided by Dr. Hassan Uludag’s group at the 
University of Alberta (Alberta, Canada). FBS was acquired from Atlanta Biologicals 
(Norcross, GA). 200 nM L-Glutamine, as well as 0.25% trypsin/2.21 mM EDTA in 
Hank’s Balanced Salt Solution were purchased from Mediatech Inc. (Manassas, VA). 
Doxorubicin (DOX) was purchased from LC Laboratories (Woburn, MA). Doxorubicin 
Hydrochloride (DOX-HCl) was purchased from MP Biomedicals LLC (Solon, OH). 
Formaldehyde Loading Dye used in gel electrophoresis was purchased from Ambion Inc. 
(Waltham, MA). Molecular weight ladders (1 kb and 100 bp DNA Ladders), and 
Penicillin/Streptomycin (10,000 units/mL Penicillin, 10 mg/mL) were purchased from 
Gibco (Grand Island, NY). Plasmid DNA encoding the Monster Green Fluorescent 
Protein (pGFP) was purchased from Promega (Madison, WI). The siRNA targeting 
MDR1 (ABCB1 or P-glycoprotein, NCBI reference sequence: NM_000927.4), ID 4123 
and Negative Control 1 siRNA (siNT) were obtained from Ambion Inc. (Waltham, MA). 
The TURBO DNA-Free Kit, HALT Protease & Phosphatase Inhibitor Cocktail, Pierce 
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BCA Protein Assay kit, SuperSignal West Pico Chemiluminescent Substrate, High-
Capacity cDNA Reverse Transcription kits, 6x DNA Loading Dye, Albumin Standards, 
and the Lipofectamine 3000 used as a positive control in transfection, were all obtained 
from Thermo Fisher Scientific (Waltham, MA). Mouse monoclonal anti-β-actin antibody 
(1:1,000) and mouse monoclonal anti-MDR1 antibody (1: 1,000) was purchased from 
Santa Cruz Biotechnology (Dallas, TX). Goat anti-mouse HRP-conjugated antibody was 
purchased from Southern Biotechnology (Birmingham, AL). 4x Laemmli Sample Buffer, 
Immuno-Blot PVDF membranes, Molecular Biology Agarose, and Precision Plus Protein 
Kaleidoscope Protein Standards used in western blotting were purchased from Bio-Rad 
Laboratories (Hercules, CA). RNeasy Mini Plus RNA isolation kit, Quantitect SYBR 
Green PCR kit, and Maxi Plasmid DNA Purification kits were purchased from Qiagen 
(Valencia, CA). Primers for RT-PCR were custom designed and purchased from 
Integrated DNA Technologies (Skokie, IL), with sequences as given: Forward Human 
GAPDH 5’- CAC CCA CTC CTC CAC CTT TG -3’ Reverse Human GAPDH 5’- CCA 
CCA CCC TGT TGC TGT AG -3’ Forward Human MDR1 5’- TCG CCT GGA TTC 
CCT CCT C -3’ Reverse Human MDR1 5’- AGG TCA GCA GAG CCA AGG AG -3’ 
 
4.2 Synthesis of Poly(lactide-co-glycolide)-g-poly(ethylenimine) 
The Cationic and amphiphilic copolymer poly(lactide-co-glycolide)-g-
poly(ethylenimine) (PgP) was synthesized according to methods previously described by 
Gwak et al, in which 4 kDa Poly(lactide-co-glycolide) (PLGA, 50:50) containing a 
carboxylic end group was conjugated to the primary amine group of 25 kDa 
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polyethylenimine, branched, (bPEI) by ester bonding. Once synthesized, the produced 
PgP was then purified through dialysis against deionized water using a membrane filter 
with a molecular weight cut off (MWCO) of 50 kDa. To remove any unreacted PLGA 
precipitate present the PgP was then centrifuged for 10 minutes at 5,000 rpm. The 
purified PgP was then lyophilized and stored at -20 °C. 
Structure and molecular weight of PgP was confirmed by 1H-NMR and gel permeation 
chromatography (GPC), respectively, as previously described.132 
 
4.3 Plasmid Amplification and Purification 
The plasmid encoding Monster Green Fluorescent Protein (pGFP) was obtained 
from Escherichia coli DH5α Transformed and amplified in Lysogeny broth on a shaker 
plate at 250 rpm for 12 hours at 37 °C. The Endofree Maxi Plasmid Purification Kit was 
used to isolate and purify the plasmid according to the manufacturer’s protocol. Purity 
and concentration of pGFP was determined via spectrophotometry using the Biotek 
Synergy HT plate reader. 
 
4.4 Cell Culture 
The human cell line MDA-MB-435 (both WT and ADR) were cultured in RPMI 
1640 cell medium supplemented with 10% Fetal Bovine Serum (FBS), 1% penicillin-
streptomycin (p/s), and 1% L-Glutamine at 37 °C and 5% CO2. Drug resistance in MDA-
MB-435 ADR cells was maintained through weekly treatments of 0.2 μg/mL DOX-HCl.  
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4.5 Transfection Efficiency and Cytotoxicity of PgP/pGFP Complexes 
4.5.1 Transfection Efficiency of PgP/pGFP polyplexes 
Transfection efficiency of PgP/pGFP polyplexes was determined by transfection 
of MDA-MB-435 ADR and WT cells with PgP/pGFP complexes, followed by analysis 
with fluorescent imaging and flow cytometry.  
MDA-MB-435 cells (1.2 x105 cells/well) were seeded in 12-well plates 
containing 1 mL of complete media and cultured for 24 hours. Media was then aspirated 
and replaced with RPMI 1640 supplemented with 10% FBS and 1% L-Glutamine, and 
PgP/pGFP complexes added. PgP/pGFP complexes were prepared immediately prior to 
transfection, and were formed at N/P ratios of 30:1, 45:1, and 60:1 in sterile deionized 
water and incubated for 30 minutes at 37 °C. Controls used in this experiment included 
untreated cells, cells treated with naked pGFP, and cells treated with pGFP complexed 
with PEI at a N/P ratio of 7:1. Cells were then incubated for 24 hours, at which point all 
wells were washed three times with media and were left to incubate an additional 24 
hours.  
At 48-hours post-transfection, GFP-expressing cells were imaged using an 
inverted fluorescent microscope. After imaging, cells were washed with PBS and 
incubated for 10 minutes in 250 μL of 0.25% trypsin. 500 μL of media was then added to 
each well, and samples were briefly triturated before being removed to Eppendorf tubes 
for analysis by flow cytometry. Results were gated by size to eliminate cell fragments 
and groups of clumped cells, and by fluorescence set as the lowest point at which 
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untreated cells showed 0% transfection in order to control for low levels of auto 
fluorescence. 
 
4.5.2 Cytotoxicity of PgP complexed with pGFP 
To determine the cytotoxicity of PgP as a vector for pDNA, a cytotoxicity study 
was performed in parallel experiments to the transfection efficiency study outlined in 
section 3.8.1. and using the same transfection procedure given above. MDA-MB-435 
cells were used for this experiment as well, transfected with PgP/pGFP polyplexes 
complexed at N/P ratios of 30:1, 45:1, and 60:1 in sterile deionized water, and control 
groups once again included untreated cells, cells treated with naked pGFP, and cells 
treated with pGFP complexed with PEI at a N/P ratio of 7:1.  
Cell viability was then determined by MTT assay performed according to the 
following procedure. At 48-hours post-transfection, all wells were rinsed three times with 
media. Cells were then incubated for 4 hours at 37 °C in 500 μL of serum-free media and 
120 μL of 2 mg/mL Thiazolyl Blue Tetrazolium Bromide (TBTB) in PBS. After 
incubation, cells were rinsed with PBS and 1 mL of DMSO added to all wells. The plate 
was wrapped in foil and placed on an orbital shaker for 10 minutes to allow for complete 
dissolution of the formazan crystals formed during their incubation with TBTB. DMSO 
was removed to a 96-well plate and the absorbance at 570 nm measured in triplicate 
using a Biotek Synergy HT plate reader. Relative cell viability was calculated as Cell 
Viability (%) = (OD570 (sample)/OD570 (control))*100 
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4.6 Heparin Competition Assays 
While the ability of PgP to successfully bind, protect, and deliver pDNA has been 
previously established,132 this study was proposed in order to determine the binding 
strength of PgP to siRNA relative to that of pDNA. 1% and 2% agarose gels were 
prepared with a 12-well comb and used for pGFP and siMDR1, respectively, both stained 
with 0.2% ethidium bromide. Polyplexes were prepared at N/P ratios of 30:1, 45:1, and 
60:1 with either pGFP or siMDR1, controlling for 0.1 μg of nucleic acid per well. 
Samples were then incubated for 30 minutes at 37 °C to allow stable and consistent 
complex formation. Heparin was added to the complexed samples in varying 
concentrations, measured by weight ratio of heparin to nucleic acid in the sample. After 
the addition of heparin, samples were incubated for one hour at 37 °C and then loaded 
into the gels using formaldehyde loading dye or 6x DNA loading dye. Samples were 
electrophoresed at 80 V for 60 minutes, and visualized with the ChemiDoc-It system 
using an ethidium bromide filter and UV illumination. 
 
4.7 Knockdown Efficiency and Cytotoxicity of PgP/siMDR1 Complexes 
4.7.1 Cytotoxicity of PgP/siMDR1 Complexes 
In order to evaluate if PgP/siMDR1 complexes cause toxicity to cells, whether 
due to the particle, the introduction of siMDR1, or by any other means, a cytotoxicity 
study was performed. MDA-MB-435 ADR cells (6 x104 cells/well) were seeded into 24-
well plates containing complete media and cultured for 24 hours prior to transfection. 
Following the previously outlined transfection procedure, PgP/siMDR1 complexes 
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formed at N/P ratios of 30:1, 45:1, and 60:1 in sterile nuclease-free water were added to 
wells with 500 μL of complete media. Control groups for this experiment included 
untreated cells, and cells treated with Lipofectamine 3000 carrying siMDR1. Dose was 
controlled for treatment groups by siMDR1 amount: 1 μg/well. One deviation from the 
transfection procedure outlined in section 4.5.1, aside from the control groups and nucleic 
acid use, was that the Lipofectamine 3000 treated groups were cultured for 48 hours in 
transfection media as instructed by the manufacturer, rather than the sequential 24 hour 
incubations in transfection media and normal media performed on all other groups. 
Following the MTT protocol outlined in section 4.5.2, cells were rinsed with PBS thrice 
at 48 hours post-transfection and incubated for 4 hours in serum-free media and TBTB 
dissolved in PBS. Cells were rinsed three more times in PBS and 1 mL of DMSO added 
to all wells. The plate was wrapped in foil and placed on an orbital shaker for 10 minutes 
to allow for complete dissolution of the formazan crystals formed during their incubation 
with TBTB. DMSO was removed to a 96-well plate and the absorbance at 570 nm 
measured in triplicate using a Biotek Synergy HT plate reader. Relative cell viability was 
calculated as Cell Viability (%) = (OD570 (sample)/OD570 (control))*100 
 
4.7.2 MDR1 Silencing 
The degree of MDR1 silencing by PgP-mediated transfection with siMDR1 was 
quantified in MDA-MB-435 ADR cells. MDA-MB-435 ADR cells were transfected 
using the same procedure as outlined in 4.7.1, in 24-well plates seeded at 6x104 cells/well 
and cultured for 24 hours prior to transfection. Polyplexes were formed at N/P ratios of 
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30:1, 45:1, and 60:1 in sterile nuclease free water and incubated at 37 °C for 30 minutes 
to allow formation of stable complexes. Control groups included untreated cells and cells 
treated with Lipofectamine 3000 delivering siMDR1. At 48-hours post-transfection, cells 
were harvested and isolated for either protein or RNA, to evaluate the MDR1 expression 
level by western blot in protein level and real-time PCR (RT-PCR) in mRNA level, 
respectively.  
i) Western blot 
At 48 hours after transfection, cells were washed with PBS and then lysed with 
RIPA buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.5% sodium deoxycholate, 0.1% 
SDS, and 1% triton-x) containing 0.1% Halt Protease & Phosphatase Inhibitor Cocktail 
(see 3.1: materials), all chilled to 4 °C prior to addition into the well plate. Wells were 
scraped using the rubber plunger of a 1 mL syringe, briefly triturated, and removed to 
Eppendorf tubes which were then placed on ice for 10 minutes to allow complete cell 
lysis. Samples were briefly vortexed at low speed and then centrifuged at 10,000 rpm and 
4 °C for 15 minutes, after which samples were removed to new Eppendorf tubes without 
disturbing the pellet formed during centrifugation. Concentration of the samples was 
determined by BCA assay using the Pierce BCA Protein Assay Kit, performed according 
to the manufacturer’s protocol. 10 μg of protein lysates from each sample were then 
loaded into SDS-Page gels and run for 15 minutes at 150 V, followed by 90 minutes at 
120 V once samples had entered the stacking gel. Proteins were then transferred to 
Immuno-Blot Polyvinylidene fluoride (PVFD) membranes for one hour at 100V. 
Membranes were then submerged in blocking solution (4% Bovine Serum Albumin 
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(BSA) in Tris-HCl buffered saline with 0.1% Tween-20 (TBST)), for one hour at room 
temperature on an orbital shaker at low speed. After blocking, primary antibody binding 
was accomplished by incubating the membranes in blocking solution containing either 
mouse monoclonal anti-MDR1 antibody (1:800 dilution) or mouse monoclonal anti-β-
actin antibody (1: 1,000) for 16 hours at 4 °C. Membranes were then thrice washed for 5 
minutes in TBST and incubated in blocking solution containing horseradish peroxidase 
(HRP) conjugated goat anti-mouse secondary antibody (1: 8,000) for one hour at room 
temperature. Membranes were once again washed for 5 minutes in TBST three times 
followed by a 5-minute incubation at room temperature with 1 mL of SuperSignal West 
Pico Chemiluminescent Substrate. Membranes were then sealed in plastic wrap and 
imaged using the ChemiDox-It system with no filter applied and an exposure time of 5 
minutes.  
ii) RT-PCR 
At 48 hours post-transfection, cellular RNA was isolated and purified using the 
RNeasy Mini Plus Kit according to the manufacturer’s protocol. Genomic DNA (gDNA) 
was eliminated using the TURBO DNA-Free Kit, after which the concentration and 
purity of RNA samples was determined by absorbance at 260, 280, and 320 nm measured 
with a Take3 Micro-Volume Plate and a Biotek Plate Reader. 10 µg of each RNA sample 
was then reverse transcribed into cDNA using the High-Capacity cDNA Reverse 
Transcription Kit with MultiScribe Reverse Transcriptase according to manufacturer 
instructions. RT-PCR was performed in duplicate for all samples using the Quantitect 
SYBR Green PCR Kit, a Rotor Gene Q thermal cycler, and IDT custom forward and 
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reverse primers for MDR1 and the endogenous control gene GAPDH. A RT-PCR 
standard curve was generated using RNA samples isolated from untreated MDA-MB-435 
ADR cells to determine the amplification efficiency of the target and reference genes, 
calculated from the slope of the standard curve (CT vs. log(quantity)) with the equation e 
= 10-1/slope and found to be within 0.05 of 100% efficient for both genes, with R2 values of 
> 0.997. The cycle number at which the fluorescence detected was greater than the 
threshold line of 0.02, or threshold cycle (CT), was determined for GAPDH and MDR1 in 
all samples and relative mRNA expression of MDR1 calculated using the ΔΔCT method, 
where ΔCT = CT (Target) - CT (Reference), ΔΔCT = ΔCT (Sample)-ΔCT (Control), and relative 
expression (%) = 2-ΔΔCt. Controls for all samples run were prepared without reverse 
transcriptase during reverse transcription (-RT) and used in all RT-PCR experiments as 
negative controls to identify gDNA contamination, and each RT-PCR experiment 
included a no-template control (NTC). Melt curve analyses were performed following 
each run and indicated no formation of primer dimers, nonspecific binding, or other 
potential sources of error in the procedure.  
 
4.8 Doxorubicin Loading in PgP 
To load doxorubicin (DOX) in PgP, the hydrophobic drug DOX was first 
dissolved in methanol at varying concentrations and added to samples of 1 mg/mL PgP at 
a 1:10 ratio (v/v), therefore the concentration of DOX in methanol was 10x the final 
loading concentration used to calculate loading efficiencies and capacities. The samples 
were shaken for 4 hours at room temperature, and left overnight to allow for methanol 
 39 
evaporation. After complete evaporation of methanol, sterile deionized water (DW) was 
added to supplement water loss due to evaporation and the samples were briefly 
centrifuged. Samples were then filtered using 0.2 μm PES membrane syringe filters. 
Absorbance of the samples at 520 nm was measured using a Biotek Synergy HT 
plate reader, and DOX concentration of each sample was calculated by Beer’s law. The 
standard curve was made using doxorubicin-HCl (DOX-HCl) in deionized water in 
concentrations ranging from 0.025-0.5 mg/mL and samples read were diluted with a 
dilution factor of 5 to prevent detector saturation. Entrapment efficiency was calculated 
as EE=drug loaded (weight)*100/total drug (weight). Loading capacity was calculated as 
LC (%)=drug loaded (weight)*100/Nanoparticle (weight), used to quantify the drug 
content of the particle irrespective of its presence in the medium. 
 
4.9 Cytotoxicity of Doxorubicin-loaded PgP 
The cytotoxicity of Doxorubicin-loaded PgP (DOX/PgP) was determined by MTT 
assay performed on MDA-MB-435 ADR cells after treatment with DOX/PgP. Cells were 
seeded in 24-well plates at a concentration of 6 x104 cells/well, using a working volume 
(500 uL) of complete medium and incubated for 24 hours. Cell medium was then 
replaced with RPMI 1640 cell medium supplemented with 10% FBS and 1% L-
Glutamine. DOX/PgP was prepared as outlined in section 4.8 at a loading concentration 
of 1 mg/mL doxorubicin and diluted with DW to varying concentrations of DOX ranging 
from 1-25 μM (determined by previously outlined loading study) and a final volume of 
50 μL/well. Control groups consisted of untreated cells, cells treated with equivalent 
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concentrations of DOX-HCl, and cells treated with equivalent concentrations of PgP 
alone. Cells were then incubated for an additional 24 hours, at which point all wells were 
rinsed three times with media. Cells were then incubated for 4 hours at 37 °C in 500 μL 
of serum-free media and 120 μL of 2 mg/mL Thiazolyl Blue Tetrazolium Bromide 
(TBTB) in PBS. After incubation, cells were rinsed with PBS and 1 mL of DMSO added 
to all wells, and the plate was wrapped in foil and placed on an orbital shaker for 10 
minutes to allow for complete dissolution of the formazan crystals formed during their 
incubation with TBTB. DMSO was then removed to a 96-well plate and absorbance at 
570 nm measured in triplicate using a Biotek Synergy HT plate reader. Relative cell 
viability was calculated as Cell Viability (%) = (OD570 (sample)/OD570 (control))*100 
  
4.10 Combinatorial Therapy of Doxorubicin and siMDR1 by PgP 
To evaluate the synergistic effect of MDR1 gene knockdown and DOX treatment, 
we performed 2 different treatment methods, 1) co-delivery of DOX/PgP/siMDR1 and 2) 
sequential treatment of PgP/siMDR1 and then DOX/PgP. 
i) Cytotoxicity of co-delivery of DOX/PgP/siMDR1 in MDA-MB-435 ADR cells 
The cytotoxicity of co-delivered DOX and siMDR1 was determined by treatment of 
MDA-MB-435 ADR cells with DOX-loaded PgP (2.36 μg DOX for N/P ratio of 30:1 and 
3.54 μg DOX for N/P ratio of 45:1) complexed with siMDR1 (1 μg siMDR1 for N/P ratio 
of 30:1 and 45:1). DOX/PgP/siMDR1 complexes were prepared by first loading DOX in 
PgP according to the procedure outlined in section 4.8 using a DOX loading 
concentration of 1 mg/mL in PgP (1 mg/mL) and confirmed by absorbance at 520 nm. 
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DOX/PgP samples were then complexed with siMDR1 at N/P ratios of 30:1 and 45:1 in 
sterile nuclease-free water and incubated for 30 minutes at 37 °C, prepared immediately 
prior to addition into the wells. Cells were seeded 24 hours prior to transfection in 24-
well plates (6 x104 cells/well). Controls for this experiment included untreated cells, and 
cells treated with PgP alone, DOX-HCl, DOX/PgP, PgP/siNT, PgP/siMDR1, and 
DOX/PgP/siNT. Cells were incubated for 24 hours, at which point wells were rinsed and 
replaced with complete media, followed by an additional 48-hour incubation. 72 hours 
after treatment, cell viability was measured by MTT assay, using the same methods as 
those outlined in chapter 4.5.2.  
ii) Cytotoxicity of sequential treatment of PgP/siMDR1 and DOX/PgP  
The cytotoxicity of sequential treatment of DOX and siMDR1 was determined by 
treatment of MDA-MB-435 ADR cells with PgP/siMDR1 first and then treated with 
DOX-HCl. PgP/siMDR1 polyplexes (1 µg siMDR1 for N/P ratios of 30:1 and 45:1) was 
transfected in MDA-MB-435 ADR cells in parallel to the co-delivery study outlined 
above using the same methods. At 48 hours after transfection, all cells were then treated 
with DOX-HCl, at an equivalent dose to that of DOX loaded in PgP for the given N/P 
ratio used (9 µM and 13.5 µM for N/P ratios of 30:1 and 45:1, respectively). After an 
additional 24-hour incubation, a total of 72 hours after treatment with PgP/siMDR1 
polyplexes, cell viability was measured by MTT assay, using the same methods as those 
outlined in chapter 4.5.2. 
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4.11 Statistical Analysis 
 Quantitative data is presented all figures as mean ± SEM. Statistical analyses 
between two groups were performed with a Student’s t-test, and analysis among multiple 
groups was performed using a one- way analysis of variance (ANOVA). Results were 
considered statistically significant when P < α, where α = 0.001 for RT-PCR results, and 
α = 0.05 for all other experiments. All calculations for statistical analysis were performed 
using the Analysis ToolPak program within Microsoft Excel.  
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CHAPTER 5 
RESULTS 
 
5.1 Transfection Efficiency and Cytotoxicity of PgP/pGFP Polyplexes 
 Qualitative analysis by fluorescent microscopy showed successful uptake of the 
particle by the MDA-MB-435 ADR cells, indicated by the expression of GFP which is 
visible in figure 3. As expected, no fluorescence was visible in cells treated with naked 
pGFP, having no inherent mechanism to facilitate entry into the cytosol. Cells treated 
with pGFP/PEI showed very little fluorescence in terms of both intensity and the number 
of cells exhibiting GFP Fluorescence, due to its poor stability in serum conditions. Of the 
cells treated with PgP, the N/P 60:1 and 30:1 groups appeared to have similar proportions 
of cells producing GFP, however the fluorescing cells within the 60:1 treated groups 
showed a markedly higher intensity of fluorescence than those treated with complexes 
formed at N/P 30:1. The results, given in figure 4, are consistent with fluorescent 
imaging, showing very low transfection in PEI and highest transfection in the 60:1 groups 
and statistical significance between the PgP N/P 30:1 and 60:1 groups in both the wild 
type and ADR cells at an alpha value of 0.05. Groups treated with naked pGFP showed 
no significant transfection in comparison to untreated groups, reiterating the need for a 
delivery system in transfection with pDNA.  
Results of the cytotoxicity experiment, given in figure 5, showed minimal toxicity 
in the groups treated with PgP at N/P ratio of 30:1, with a strong positive correlation 
between the N/P ratio used and cytotoxicity in all PgP-treated groups. Actual percent 
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viability for all ADR groups relative to the control were 105%, 92%, 77%, 70%, and 90% 
for PEI 7:1, PgP 30:1, 45:1, and 60:1, and Lipofectamine 3000, respectively. A similar 
trend was observed in the wild type groups, with cell viabilities of 98%, 80%, 65%, and 
45% for PEI 7:1, PgP 30:1, 45:1, and 60:1, respectively. In summary, this study has 
shown that PgP can be used for delivery of nucleic acid into the cytosol of drug resistant 
human cancer cells such that they can then function, and that there is potentially an ideal 
N/P ratio in which transfection efficiency can be maximized while mitigating any  
Figure 3. Visualization of transfection by GFP expression in MDA-MB-435 Cells. Both Wild Type (left) and ADR 
cells (right) were treated with naked pGFP (control), PEI (N/P 7:1) and PgP/pGFP complexed at N/P ratios of 30:1, 
45:1, and 60:1. In these images, taken 48 hours after transfection, PgP is shown to successfully mediate delivery of 
pDNA to the intracellular compartment for release within the cytosol.  
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Figure 4. Transfection Efficiency of PgP/pGFP complexes in MDA-MB-435 ADR Cells. Measured by flow 
cytometry in analysis of GFP expression 48 hours after transfection with naked pDNA, PEI (N/P 7:1), and PgP 
(N/P 30:1 and 60:1). Data shown is mean ± SEM of three independent experiments (N=3) in which all groups were 
run in triplicate. Significance was found for all PgP/pGFP groups compared to untreated cells, and significance 
found between WT and ADR for PEI and PgP/pGFP 60:1 (P<0.05, Student’s t-test).  
Figure 5. Cell Viability of MDA-MB-435 ADR cells 48 hours after treatment with PgP/pGFP. Relative Cell 
Viabilities shown were determined via MTT assay and read by absorbance at 570 nm in 96-well plates. Groups 
shown are (left to right) Untreated cells, PEI/pGFP at N/P ratio 7:1, PgP/pGFP at N/P ratio 30:1, PgP/pGFP at N/P 
ratio 45:1, PgP/pGFP at N/P ratio 60:1, and pGFP loaded in Lipofectamine 3000. Data is given as mean ± SEM of 
four independent experiments (N=4) performed in triplicate. Significant difference (P<0.05) was found between 
WT and ADR cells in all PgP/pGFP groups. 
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cytotoxic effect of the particle for use as a non-viral vector in therapeutic gene therapy 
with siRNA. 
 
5.2 Heparin Competition Assay 
 PgP has previously been shown to effectively mediate transfection in some cell 
lines with pDNA,132 however existing research suggests that within the field of synthetic 
carriers the ability of a vehicle to successfully deliver pDNA may not be as translatable to 
RNA applications as previously thought.146 To that end, a heparin competition assay was 
performed on PgP/pGFP and PgP/siMDR1 polyplexes to assess the binding strength of 
siRNA relative to that of pDNA. Heparin, due to its strong negative charge, will compete 
with nucleic acids present in the complex to electrostatically associate with amine groups 
in the corona of the PgP micelles, ultimately causing nucleic acid to dissociate from the 
complex when present in high enough concentration. For this study, PgP was complexed 
with either pGFP or siMDR1 at N/P ratios of 30:1, 45:1, and 60:1 and incubated with 
varying concentrations of heparin, measured here by their weight ratio (WR) to the 
nucleic acid present, and compared to naked siMDR1 or pGFP corresponding with the 
complex used. Imaging of the gels after electrophoresis show that PgP/pGFP complexes 
consistently begin to dissociate at much higher weight ratios of heparin, indicating a 
lower competitive stability in siMDR1-containing complexes. Displacement of pGFP can 
be seen occurring at WRs of 6:1, 9:1, and 12:1 for complexes formed at N/P ratios of 
30:1, 45:1, and 60:1, respectively, while in PgP/siMDR1 complexes dissociation is seen 
much earlier, at WRs of 3:1, 4:1, and 6:1. PgP/pGFP complexes at N/P 30:1. Although 
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displacement of siMDR1 begins much earlier than pGFP in PgP complexes, partial 
displacement of siMDR1 can be seen over a much larger range than in pGFP groups. 
Complete dissociation (as can be referenced by the naked nucleic acid group in each 
image) of siMDR1 from PgP only occurs after a large range of partial displacement, at 
weight ratios of 5:1, 9:1, and 10:1 – much closer to those at which pGFP completely 
dissociates.  
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5.3 PgP-Mediated Delivery of siMDR1 
 In order to assess the ability of PgP to deliver siMDR1 to cells and that the siRNA 
delivered succeeds in silencing the gene coding for P-glycoprotein (MDR1), MDA-MB-
435 ADR cells were transfected with PgP/siMDR1 complexes formed at N/P ratios of 
Figure 6. Heparin competition assay. Competitive dissociation of PgP/pDNA in the presence of heparin at varying 
weight ratios (Heparin/Nucleic acid ratio). Samples shown are (left to right) naked nucleic acid, followed by polyplex 
samples incubated in increasing ratios (w/w) of heparin to nucleic acid in the sample. A) PgP/pGFP (N/P 30:1) B) 
PgP/siMDR1 (N/P 30:1) C) PgP/pGFP (N/P 45:1) D) PgP/siMDR1 (N/P 45:1) E) PgP/pGFP (N/P 60:1) F) 
PgP/siMDR1 (N/P 60:1) 
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30:1, 45:1, and 60:1, and examined for silencing of MDR1 at the mRNA and protein 
levels as well as the cytotoxicity of the doses used to produce samples for these 
knockdown experiments. To assess MDR1 expression on the protein level, the protein 
levels of each group determined by BCA assay, and each sample analyzed by western 
blotting for MDR1 expression with β-actin chosen as an endogenous control for 
normalizing protein level per lane (MDR1 ~170 kDa, β-actin ~42 kDa). Visually, MDR1 
protein expression (shown in figure 7) in the control band appears much higher than in 
the knockdown groups, and when normalized the relative expression of MDR1 was found 
to be at 52%, 23%, 21%, and 29% when compared to the control for PgP 30:1, 45:1, 
60:1, and Lipofectamine 3000, respectively.  Silencing of MDR1 at the mRNA level was 
assessed by RT-PCR, and results given in figure 8. The expression of mMDR1 was 
normalized using GAPDH as an endogenous control and within 0.5 Ct of the GAPDH CT 
value found of the control group. All groups showed significant knockdown in 
comparison to untreated cells, with PgP complexed at N/P ratios of 30:1, 45:1 and 60:1 
showing relative gene expressions of 76%, 65%, and 33%, respectively. Cytotoxicity of 
these groups was assessed via MTT assay, the results of which are shown in figure 9. In 
consideration of both the silencing and cytotoxicity results, N/P 45:1 PgP was selected to 
move forward with in future studies. 
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Figure 7. Western blot analysis of MDR1 expression following treatment by 
PgP/siMDR1. Results reflect MDR1 protein levels in MDA-MB-435 ADR cells at 48 
hours after treatment with siMDR1 containing complexes of PgP prepared at N/P 
ratios of 30:1, 45:1, and 60:1, with untreated cells as the negative control (left) and 
Lipofectamine 3000 used as a positive control (right). Β-actin was used to normalize 
results for densitometric analysis  
Figure 8. Relative expression of MRD1 after knockdown by PgP/siMDR1 polyplexes by RT-PCR. Results of RT-
PCR analysis of MDA-MB-435 ADR cells harvested 48 hours after treatment. Samples shown were (from left to 
right) untreated, treated with PgP/siMDR1 polyplexes complexed at N/P ratios of 30:1, 45:1, and 60:1, and 
siMDR1 loaded in Lipofectamine 3000. GAPDH was used as an endogenous control. Data is given as mean ± SEM 
of four independent experiments performed in triplicate where *P<0.0001, (student’s t-test) in comparison to 
untreated cells. 
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5.4 Doxorubicin Loading in PgP 
 Based on the intercalating mechanism through which it functions, a means of 
intracellularly delivery can significantly improve the efficacy of Doxorubicin. Given the 
established ability of PgP to deliver pDNA into the cytosol of cancer cells, the capacity of 
PgP as a carrier for DOX was examined. As shown in figure 10, the ability of PgP to 
entrap doxorubicin, given by loading capacity, showed a clearly defined positive 
correlation with the total amount added. However, the entrapment efficiency declined 
significantly as a result. No steep decline in entrapment efficiency was observed for the 
concentrations of DOX used that would indicate an approaching maximum capacity of 
PgP, however the amount of DOX that could be loaded in this analysis was constrained 
Figure 9. Cytotoxicity of MDA-MB-435 ADR Cells After Treatment with PgP/siMDR1. Relative cell viability was 
determined by MTT assay with untreated cells, cells treated with PgP/siMDR1 complexed at N/P ratios of 30:1, 
45:1, and 60:1, as well as siMDR1 loaded into Lipofectamine 3000. Data shown is mean ± SEM of three 
independent experiments performed in triplicate. Results were found to be significant (P<0.05) by one-way 
ANOVA. 
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by the solubility limit of DOX in methanol used in the loading process. Given these 
results, PgP has shown it can be successfully loaded with DOX, and based on the 
encapsulation efficiency of DOX/PgP as well as the amount of PgP required for effective 
transfection, an initial DOX concentration of 1 mg/mL was selected as the loading 
parameter for further studies with PgP/DOX. 
 Cytotoxicity of DOX-loaded PgP was determined by MTT assay, in comparison 
to untreated cells, as well as cells treated with PgP alone or DOX-HCl. As shown in 
figure 10, a clear increase in cytotoxicity is observed in DOX/PgP treated groups, 
however the relative cell viabilities of the groups tested leave it unclear if this increase is 
due to any synergistic effect of the PgP such as an improved efficacy due to intracellular 
delivery of DOX.  
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Figure 10. Doxorubicin Loading in PgP. (Left) Entrapment Efficiency of Doxorubicin in PgP, calculated as the 
amount of drug loaded divided by the total drug added (Right) Loading Capacity of Doxorubicin in PgP, the actual 
ability of the particle to entrap DOX, and calculated as the Loading= loaded drug (weight)*100/PgP (weight). Data 
is given as mean ± SEM of three independent studies performed in triplicate. 
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5.5 Combinatorial Therapy of Doxorubicin and siMDR1 by PgP 
 To determine the practical efficacy of the fully assembled DOX/PgP/siMDR1 
particle, Cytotoxicity studies were performed using MTT assays of MDA-MB-435 ADR 
cells treated both concurrently and sequentially with PgP/siMDR1 and Doxorubicin, 
using complexes prepared at N/P 45:1. For assessing the ability of co-delivered siMDR1 
and DOX to treat drug resistant cells, groups were treated with DOX-HCl alone, PgP and 
DOX-loaded PgP complexed with siMDR1, and formulations of PgP or DOX-loaded PgP 
either alone or complexed with non-targeting siRNA (siNT). As seen in Figure 12, all 
groups treated with doxorubicin loaded PgP showed significant cytotoxicity over other 
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Figure 11. Cytotoxicity of DOX-Loaded PgP Micelles. Doxorubicin was loaded into PgP micelles with an initial 
concentration of 1 mg/mL and loading efficiency determined at 42%. This value was used in calculating equivalent 
dose of DOX-HCl, taking into account the difference in molecular weight between DOX freebase and the HCl 
formulation. PgP dose used was equal to the dose of DOX-loaded PgP. Results are given as mean ± SEM of three 
independent experiments performed in triplicate. 
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groups, with a slight decrease in cytotoxicity observed in the DOX/PgP/siNT group 
compared to uncomplexed DOX/PgP. A significant increase in cytotoxicity was seen in 
the DOX/PgP/siMDR1 groups in comparison to non-targeting groups (DOX/PgP/siNT), 
however the greatest contributor of toxicity to treated groups appears to be doxorubicin 
delivery by PgP.  
In sequentially treated groups, treated with DOX/PgP (13.5 μM DOX) 48 hours 
after an initial transfection with PgP/siRNA, cytotoxicity was determined by MTT assay, 
the results of which are shown in figure 13. As with the co-delivery study, significantly 
higher cytotoxicity was observed in the PgP/siMDR1 groups compared to non-targeting 
(PgP/siNT) groups, however once again treatment with DOX/PgP seems to be the 
greatest contributor to toxicity even in this drug-resistant cell line. Given the static nature 
of the in vitro environment as well as the inherently time-dependent nature of siRNA-
mediated gene silencing, in vivo studies may be necessary to determine the optimal time 
frame of re-sensitization in cancer populations. Despite this, even the results of short-
term studies have demonstrated the ability of PgP in mediating both MDR1 knockdown 
as well as intracellularly delivering doxorubicin, establishing its capacity as a delivery 
vehicle for both DOX and siRNA, and justifying its potential candidacy for further 
characterization in vivo. 
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Figure 12. Cytotoxicity of PgP mediating Co-delivery of doxorubicin and siMDR1. MDA-MB-435 ADR cells were 
treated with the given groups, with all PgP doses reflecting complexation at a N/P ratio of 45:1. All groups were 
analyzed at 48-hours post treatment via MTT assay. Data is shown as mean ± SEM, with significance found 
between DOX/PgP/siNT and DOX/PgP/siMDR1 groups (P<0.05) by t-test. 
Figure 13. Cytotoxicity of sequential treatment with PgP/siMDR1 and Doxorubicin HCl. MDA-MB-435 ADR cells 
were treated with the shown groups, and 48 hours later groups indicated by ‘+DOX-HCl’ were given a second 
treatment of 13.5 μM Doxorubicin HCl. Cytotoxicity of all groups was then assessed by MTT assay at 72 hours 
after initial treatment. Data is given as mean ± SEM. Significance was found between PgP/siNT and PgP/siMDR1 
groups given a secondary treatment of DOX/PgP by t-test (P<0.05). 
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CHAPTER 6 
DISCUSSION 
 
 The goal of this project was to develop and characterize the novel polymeric 
micelle developed by this lab, PgP, for its application and utility in mitigating multidrug 
resistance in metastatic breast cancer. Establishing the safety and utility of its use in both 
doxorubicin and siMDR1 delivery could prove relevant in treatment of triple-negative 
breast cancer, such that it could improve the efficacy of normal treatment with 
chemotherapeutics of the anthracycline class characterized by their hydrophobicity and 
intercalating mechanism of function. Improving the efficacy of these drugs would result 
in a lower minimal therapeutic dose and decrease both the risks of systemic cytotoxicity 
they present as well as the rate at which drug resistance is developed in treated cancer 
populations due to the inherently cyclic nature of treatment with these drugs. Ultimately 
should these improvements be translated to clinical application they could serve to 
improve treatment in terms of both safety and patient outcomes. 
 In evaluating the results of the experiments listed in this study, a few advantages 
and shortcomings in the use of PgP as a delivery vehicle for doxorubicin and siRNA that 
should be addressed. PgP was first examined for its ability to deliver pDNA in such a 
way that it could then be functionally expressed by transfected cells. Results of these tests 
proved PgP to be an effective vector for this application, however the trade-off between 
maximizing particle efficacy and minimizing treatment toxicity is immediately apparent. 
While increases of dose and N/P ratio of the polyplex did show a positive correlation to 
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transfection efficiency in these experiments, the increase was not as linearly correlated as 
could be expected – likely a result of the increase in cytotoxicity arising from the increase 
in both dose and particle surface charge. Transfection efficiency of complexes formed 
with pDNA was also observed to be lower than initially hoped, however not to a degree 
that would eliminate PgP as a promising candidate for siRNA delivery. While a vector’s 
ability to transfect cells with pDNA has been a widely used method of determining its 
capacity for use in RNAi applications, pDNA and siRNA have been shown to behave 
very differently when interacting with cationic DDVs, as well as their complex’s 
subsequent interactions in the biological environment.146 The implications that this 
difference in behavior between pDNA and siRNA complexed particles could have for 
this project’s goals with PgP as a delivery vehicle were unclear, however, as the nature 
and significance of this difference seems largely dependent on the particle being 
examined and its individual charge and complexation to nucleic acid. With that in mind, 
the binding strength of PgP to siRNA relative to that of pGFP was examined at various 
N/P ratios through heparin competition, with surprising results; showing stable binding at 
significantly higher heparin concentrations in the pGFP-bound micelles, while exhibiting 
similar points of complete dissociation.  
Heparin competition revealed siRNA-bound complexes to have a lower overall 
binding strength to PgP than pGFP-containing polyplexes, although dissociation of 
nucleic acids within the complex through competition with other charged particles in 
solution occurred over a much larger range of concentrations than the pGFP-bound 
groups, which showed a nearly binary relationship when it comes to competition-driven 
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dissociation with exception to complexes formed at very high N/P ratios. This would 
imply that PgP/siRNA complexes may show the same drastic increase in efficacy at high 
N/P ratios for knockdown that the PgP/pDNA complexes did in transfecting GFP 
expression, however, as their mechanisms of function within the cytosol differ, it is 
unclear to what degree the actual amount of siRNA delivered to a cell may impact target 
gene expression.  
siMDR1 complexes consistently showed dissociation at much lower weight ratios 
of heparin, despite the fact that nucleic acid loading was controlled for all samples by 
mass, making the overall charge of the siRNA added slightly stronger than that of the 
pDNA due to the lower molecular weight of RNA base pairs. Additionally, the results of 
the heparin competition would indicate that despite the significantly smaller size of the 
siRNA, it primarily binds to the surface of the micelle in the same manner as pDNA, 
rather than interpenetrating the PEI layer of the PgP micelles to associate with deeper 
amine groups, although confirmation of this through AFM or SEM would be necessary to 
confirm this indication. 
 This test was followed by in depth assessment of MDR1 knockdown by 
PgP/siMDR1 treated groups. RT-PCR and western blot testing both showed significant 
silencing of the MDR1 gene on both a mRNA and protein level at 48 hours after 
treatment, to levels much more significant than those given by pDNA transfection 
studies. While unexpected, this is not unprecedented as PEI and its derivatives have 
shown in previous studies (albeit unreliably) for improved performance as a vehicle for 
siRNA over pDNA.146  
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 Having established the ability of PgP to mediate silencing of the gene coding for 
P-glycoprotein (MDR1), the capacity of PgP as a carrier for the hydrophobic drug 
doxorubicin was then examined. PgP was quickly determined to be capable of loading 
doxorubicin, although its release over time in serum conditions would be an interesting 
relationship to quantify, as its stability in PgP micelles in water alone would not be 
representative of its behavior in vivo due to the relative insolubility of doxorubicin in 
water and the abundance of hydrophobic compounds capable of acting as a solvent to the 
drug in biological conditions. The loading capacity and entrapment efficiency of 
doxorubicin in PgP showed normal behavior, although this relationship is likely 
dependent on the formulation of PgP apropos its PLGA chain length. With the 12 kDa 
PLGA chain present in the formulation of PgP used in this study, the maximum loading 
capacity of PgP was limited by the solubility of doxorubicin in the methanol used in the 
loading process rather than the actual solubility of doxorubicin in PgP. This could be 
overcome through the use of alternative solvents in loading, however based on the results 
found and the potential for PgP degradation by stronger organic solvents, the model used 
was found to be acceptable for this study. In consideration of PgP toxicity required dose, 
as well as the loading data with regards to the cost and dosage of doxorubicin in clinical 
applications, loading conditions of 1 mg/mL initial doxorubicin and PgP concentrations 
were selected for all subsequent studies involving DOX-loaded PgP. The relative 
cytotoxicity of DOX/PgP in comparison to DOX-HCl and PgP alone showed that 
delivery mediated by PgP micelles improved efficacy of the drug over the salt 
formulation, although at high doses beyond what would realistically be used for PgP 
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showed that it is likely the primary source of toxicity, as seen by the parallel decrease in 
cell viability exhibited by PgP and DOX/PgP groups that was not reflected in similarly 
increasing doses of DOX-HCl. To confirm the actual mechanism of toxicity in dox-
loaded PgP, whether a function of PgP exposure, its combination with doxorubicin, or 
due to intracellular delivery of DOX, a TUNEL assay may be incorporated into future 
studies. Since the function of DOX, like other anthracyclines, produces double stranded 
DNA breaks in affected cells,147 TUNEL may be useful in differentiating which of the 
possible factors contribute most heavily to the observed increase in cytotoxicity by 
DOX/PgP treatments. 
 The results of the in vitro studies would, at this point, merit progression to in vivo 
characterization of its biocompatibility and antitumor effects, however both time and 
fiscal restraints dictated further in vitro examination into the practical advantages of co-
delivering siMDR1 and doxorubicin. While the DOX/PgP/siMDR1 treated groups 
showed radically lower cell viability than those treated with equivalent doses of DOX-
HCl, this was likewise reflected in both the non-targeting groups (DOX/PgP/siNT) and 
the unbound DOX/PgP groups, prompting us to consider the time-dependent nature of 
RNAi-mediated gene silencing. The effects of sequential treatment with PgP/siMDR1 
followed by doxorubicin-HCl was examined, and these results did show significant 
cytotoxicity of the siMDR1-treated cells in comparison with non-targeting groups, 
however not to the scale or degree expected given the knockdown results. While this 
could indicate the need to address another mechanism of resistance, such as bcl-2 
dependent resistance, with siRNA in conjunction to the multidrug resistance mediated by 
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P-glycoprotein, it may simply represent the limitations of in vitro analysis of the particle 
at this stage. Given the static nature of the in vitro studies available to this lab, a more 
translatable model may be needed. Additionally, determining the time frame and relevant 
toxicities of optimum treatment may require a more complex model when considering the 
time frame of transfection and siRNA-mediated gene silencing. While mRNA levels will 
decrease within 24 hours of siRNA-mediated gene silencing, maximum silencing will 
often be reached at a later point, usually sometime between 24 and 48 hours following 
transfection. Functional protein levels, being further downstream, will take even longer to 
reflect changes in RNA expression and are heavily dependent on the nature of the protein 
in question and its stability within the experimental system.  
 Certainly, based on the ability of PgP/siMDR1 complexes to facilitate knockdown 
of MDR1, as well as its ability to intracellularly delivery doxorubicin, PgP shows 
potential as a vehicle for mediating multidrug resistance in cancer. Following in vivo 
characterization, modifying the siRNA target to alternative or additional genes 
responsible for drug resistance such as those in the bcl-2 resistance pathway, or further 
downstream the pump-dependent (MDR1) pathway may serve to improve treatment 
efficacy. Including siRNA targeting genes responsible for other proteins essential in 
metastatic site development such as VEGF or HIF-1α (critical in angiogenesis and 
directing metastatic proliferation) could also serve to impede proliferation of non-
transfected cells within the tumor or pre-tumor environment. Another potential 
modification to the vector that could be investigated is conjugation to a targeting moiety. 
Currently, PgP micelles remain a 1st generation nanoparticle in that they contain no 
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mechanism for specificity beyond passive targeting via the EPR effect. Potential 
mechanism for targeting could include conjugation to growth factors matched to 
upregulated receptors in target cancer populations (2nd gen.), or even conjugation to 
specific antibodies targeting cancer cells (3rd gen.). One potential setback to consider in 
this modification would be the proximity of a given targeting moiety to the charged PEI 
corona of the micelles, therefore potential implementation of a hydrophilic spacer should 
be considered as well – such as polyethylene glycol or other similar groups. Lastly, 
complexation with siRNA supramolecular assemblies could also prove to act 
synergistically with their previously established improvements on traditional siRNA in 
terms of functionality,148 although this is purely speculative and would require additional 
characterization of the complex, as incorporation of these structures may impact the 
polyplex morphology, charge, or behavior in unforeseen ways as a result of their size and 
flexibility, similarly to the differences in behavior observed in pDNA and siRNA-bound 
complexes. 
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CHAPTER 7 
CONCLUSIONS 
 In conclusion, PgP has been definitively proven to effectively complex with 
siRNA and mediate successful delivery into the cytosol of MDA-MB-435 ADR cells. In 
comparison to PEI it has shown to be drastically more effective in serum conditions, 
making it much more relevant to therapeutic applications. While moderate cytotoxicity 
has been observed in higher N/P ratio complexes, those formed at N/P 45:1 and 30:1 
show acceptably low cytotoxicity to justify further assessment in vivo. Moreover, 
PgP/siMDR1 complexes have been shown to significantly reduce expression of MDR1 at 
the mRNA level in vitro, with reductions as high as 67% observed in the N/P 60:1 
complexes. In terms of its ability to deliver doxorubicin, PgP has shown to be an 
effective carrier of the drug and even improve efficiency of the drug in clinically relevant 
doses. The process of loading is simple and rapid, and compatible with 0.2-micron filter 
purification.  
Overall, PgP has shown to be a promising vector for siRNA delivery in drug 
resistant cancer cells, and further development in terms of its conjugation with a targeting 
moiety may result in a clinically relevant vector for not only treatment of multidrug 
resistance, but a range of applications within the field of gene therapy.  
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